Free Trial
NASDAQ:OCS

Oculis Q2 2026 Earnings Results & Report

Oculis logo
$7.61 -0.03 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$7.63 +0.02 (+0.30%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oculis beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.20 versus the -$0.48 consensus estimate, while revenue of $383.29 thousand topped the $217 thousand estimate by $166.29 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Oculis EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.28
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Oculis Revenue Results

Actual Revenue
$383.29 thousand
Expected Revenue
$217 thousand
Beat/Miss
Beat by +$166.29 thousand
YoY Revenue Growth
N/A

Earnings Documents

Oculis Q2 2026 Earnings FAQ

Oculis (NASDAQ:OCS) reported earnings of -$0.20 per share for Q2 2026, beating the consensus estimate of -$0.48. The report was announced on Thursday, August 6, 2026.

Oculis reported revenue of $383.29 thousand for Q2 2026, against a consensus estimate of $217 thousand.

Oculis Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Oculis Gains FDA IND Clearance for Privosegtor in Acute MS Relapses
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS) is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations.

Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development.

Oculis focuses on developing treatments for patients worldwide. Its therapies remain investigational, and the company’s work is centered on advancing candidates through clinical testing and regulatory review.

View Oculis Profile